Showing 7921-7930 of 8647 results for "".
- Gilead Says Early Results of Coronavirus Drug Trial Show Improvement With Shorter Remdesivir Treatmenthttps://modernod.com/news/gilead-says-early-results-of-coronavirus-drug-trial-show-improvement-with-shorter-remdesivir-treatment/2477673/Gilead Sciences said Wednesday preliminary results of a coronavirus drug trial showed at least 50% of patients treated with a five-day dosage of remdesivir improved and more than half were discharged from the hospital within two weeks, according to a CNBC
- iSTAR Medical: Biocompatible MIGS Implant Shows Outstanding Efficacy in Glaucoma Patientshttps://modernod.com/news/istar-medical-biocompatible-migs-implant-shows-outstanding-efficacy-in-glaucoma-patients/2477668/iSTAR Medical announced positive results from two clinical trials of its micro-invasive glaucoma surgery (MIGS) implant MINIject. Both studies showed consistent reduction of IOP and reduced need for IOP-lowering medication in over 50 patients with open angle glauco
- Widely Used Surgical Masks Are Putting Health Care Workers At Serious Riskhttps://modernod.com/news/widely-used-surgical-masks-are-putting-health-care-workers-at-serious-risk/2477666/With medical supplies in high demand, federal authorities say health workers can wear surgical masks for protection while treating COVID-19 patients—but growing evidence suggests the practice is putting workers in jeopardy, according to a
- European Leaders, WHO Team Up on $8 Billion Pandemic Vaccine Responsehttps://modernod.com/news/european-leaders-who-team-up-on-8b-pandemic-vaccine-response/2477664/The leaders of Germany and France and a host of other EU countries and groups have come together with the World Health Organization (WHO) for an $8 billion push for a new vaccine against COVID-19, according to a FierceBiotech
- Clearside Biomedical Revises NDA Resubmission Timeline and Xipere Commercial Partnership with Bausch Healthhttps://modernod.com/news/clearside-biomedical-revises-nda-resubmission-timeline-and-xipere-commercial-partnership-with-bausch-health/2477660/Clearside Biomedical announced an update to the Xipere (triamcinolone acetonide suprachoroidal injectable suspension) new drug application (NDA) resubmission timeline and to its commercialization and development partnership with Bausch Health Companies and Bausch + Lomb.
- Sanofi/Regeneron and Roche Report Mixed Results for Potential COVID-19 Treatmentshttps://modernod.com/news/sanofi-regeneron-and-roche-report-mixed-results-for-potential-covid-19-treatments/2477661/Sanofi and Regeneron Pharmaceuticals said that preliminary results from the phase 2 portion of an ongoing study showed that the IL-6 receptor antibody Kevzara (sarilumab) had “no notable benefit” on clinical outcomes v
- BVI Names David Murray as Chief Financial Officerhttps://modernod.com/news/bvi-names-david-murray-as-chief-financial-officer/2477662/BVI announced that it has named David Murray as Chief Financial Officer. Most recently, Mr. Murray served as Chief Financial Officer of Alcon from 2015 until its $30bn spin-off from Novartis Group AG in 20
- Foundation Fighting Blindness To Jointly Host Online CME, COPE Webinarhttps://modernod.com/news/foundation-fighting-blindness-to-jointly-host-online-cme-cope-webinar/2477657/The Foundation Fighting Blindness has announced it will host its first continuing medical education (CME and COPE) event. The distance-learning course will be hosted on Monday, May 18, 2020 at 12 pm eastern time. The course will cover inherited retinal diseases (IRDs), Foundation resources, and c
- Seniors With COVID-19 Show Unusual Symptoms, Doctors Sayhttps://modernod.com/news/seniors-with-covid-19-show-unusual-symptoms-doctors-say/2477655/Older adults with COVID-19 have several “atypical” symptoms, complicating efforts to ensure they get timely and appropriate treatment, according to physicians, as reported by Kaiser Health News. CO
- SightGlass Vision Unveils Topline Data From Study of Novel Eyeglasses Designed to Control Myopia in Childrenhttps://modernod.com/news/sightglass-vision-unveils-topline-data-from-study-of-novel-eyeglasses-designed-to-control-myopia-in-children/2477653/SightGlass Vision announced topline data from the company’s pivotal trial evaluating its novel eyeglasses designed to slow the progression of myopia in children. Results from a planned 12-month interim analysis of the CYPRESS clinical study (NCT03623074) demonstrated a reduction in myopia p